Compare BridgeBio Pharma Inc (BBIO) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Indonesia Energy Corporation Limited — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Indonesia Energy Corporation Limited trades at $2.92 (market cap $44.93M). The key difference: BridgeBio Pharma Inc is far larger — about 369.7× Indonesia Energy Corporation Limited's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Indonesia Energy Corporation Limited nearer its low. Which is the better fit depends on your goals.
| BBIO | INDO | |
|---|---|---|
Market Cap | $16.61B | $44.93M |
Sector | Health | Energy |
52-Week High | $90.17 | $6.74 |
52-Week Low | $47.29 | $2.49 |
Enterprise Value | $18.16B | $40.30M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
INDO trades at $2.80 with a slight 0.72% daily gain. The technical picture is bearish with moving averages signaling caution, while fundamentals show significant challenges with negative profit margins (-253.4%) and weak revenue of $2M in 2025. Recent news highlights operational progress with drilling commencement at the K-29 well. Analyst consensus remains unanimously bullish with 3 buy ratings.
The outlook is speculative given deep losses, but drilling success could drive upside. Key risks include execution in exploration, sustained negative cash flow, and oil price volatility. The stock presents high-risk potential for investors betting on operational turnaround versus current financial distress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
